Premium
Adjuvant therapy for pancreas adenocarcinoma
Author(s) -
O'Reilly Eileen M.
Publication year - 2012
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23230
Subject(s) - medicine , gemcitabine , adjuvant , adjuvant therapy , adenocarcinoma , chemoradiotherapy , oncology , pancreas , overall survival , chemotherapy , cancer
Abstract Adjuvant therapy for pancreas adenocarcinoma in 2012 includes consideration of systemic therapy based on high level evidence and combined chemoradiotherapy based on less robust data. Current major adjuvant questions are examining the role of the addition of a second agent, either cytotoxic or targeted agent, to gemcitabine and whether or not the utilization of combined chemoradiotherapy improves overall survival. Progress to date has been modest and incremental in the adjuvant setting. J. Surg. Oncol. 2013;107:78–85. © 2012 Wiley Periodicals, Inc.